Prostate cancer remains a leading cause of cancer-related mortality in men, with advanced stages posing significant treatment challenges due to high morbidity and mortality. Among genetic alterations, TP53 mutations are among the most prevalent in cancers and are strongly associated with poor clinical outcomes and therapeutic resistance. This review investigates the role of TP53 mutations in prostate cancer progression, prognosis, and therapeutic development. A comprehensive analysis of preclinical and clinical studies was conducted to elucidate the molecular mechanisms, clinical implications, and potential therapeutic approaches associated with TP53 alterations in prostate cancer. TP53 mutations are highly prevalent in advanced stages, contributing to genomic instability, aggressive tumor phenotypes, and resistance to standard treatments. Emerging evidence supports the utility of liquid biopsy techniques, such as circulating tumor DNA analysis, for detecting TP53 mutations, providing prognostic value and facilitating early intervention strategies. Novel therapeutic approaches targeting TP53 have shown promise in preclinical settings, but their clinical efficacy requires further validation. Overall, TP53 mutations represent a critical biomarker for disease progression and therapeutic response in prostate cancer. Advances in detection methods and targeted therapies hold significant potential to improve outcomes for patients with TP53-mutated prostate cancer. Further research is essential to integrate TP53-based strategies into routine clinical practice.
前列腺癌仍是男性癌症相关死亡的主要原因，其晚期阶段因高发病率和高死亡率带来显著治疗挑战。在基因变异中，TP53突变是癌症中最常见的变异之一，与不良临床结局和治疗耐药性密切相关。本综述探讨TP53突变在前列腺癌进展、预后及治疗发展中的作用。通过对临床前及临床研究的综合分析，阐明TP53变异在前列腺癌中的分子机制、临床意义及潜在治疗策略。TP53突变在晚期前列腺癌中高度普遍，可导致基因组不稳定性、侵袭性肿瘤表型及对标准治疗的耐药性。新兴证据表明，液体活检技术（如循环肿瘤DNA分析）可用于检测TP53突变，具有预后价值并有助于早期干预策略的制定。针对TP53的新型治疗方法在临床前研究中显示出潜力，但其临床疗效仍需进一步验证。总体而言，TP53突变是前列腺癌疾病进展和治疗反应的关键生物标志物。检测方法和靶向治疗的进步对改善TP53突变前列腺癌患者的预后具有重要潜力。未来研究需致力于将基于TP53的策略整合到常规临床实践中。
肿瘤(癌症)患者之家